CCL2 and neoplasm: In contrast to our data, in another transplantable BRAFV600E‐murine melanoma model, BRAFi treatment led to a reduction of CCL2 mRNA expression and a reduction in secretion of CCL2 from tumor cells.11 In line, Steinberg et al. observed less CCL2 mRNA under BRAFi, which was restored in resistant tumors favoring MDSC recruitment.